SlideShare a Scribd company logo
New Drugs and Clinical
Trials (NDCT) rules, 2019
An Overview
Akash Agnihotri
Tutor
Department of Pharmacology
Amrita School of Medicine, Faridabad
NDCT 2019 by Akash Agnihotri 1
NDCT 2019
• Draft copies of new clinical trials rules on public domain: 7th February, 2018
• Objections and suggestions invited from all stakeholders
• Central Government notified “New Drugs and Clinical Trials Rules, 2019” on
19th Mar 2019
• New Drug and Clinical Trial Rules, 2019 are applicable from 19th Mar 2019,
except Chapter 4 [Ethics Committee for Biomedical and Health Research],
which came into force after 180 days (i.e. 21st Sep 2019)
2
NDCT 2019 by Akash Agnihotri
The New Drugs & Clinical Trial Rules, 2019
New rules are structured around:
• 13 chapters, which includes 107 rules and 8 schedules
Will apply to:
• All new drugs
• Investigational new drugs
• Clinical trials
• Biomedical and health research
• Ethics committees
3
NDCT 2019 by Akash Agnihotri
The New Drugs & Clinical Trial Rules, 2019
New rules override part XA and Schedule Y of medicine and
cosmetics rules, 1945
Earlier regulations and schedule Y will still be applicable for
veterinary use drugs
4
NDCT 2019 by Akash Agnihotri
Schedule Y was a law that
outlined the requirements and
guidelines for conducting clinical
trials and importing or
manufacturing new drugs in
India
Part XA As per Drugs and cosmetic Rules
1945, part X-A, import or manufacture of
new drug for clinical trials or marketing
NDCT 2019, Aimed
Promoting clinical research within the country by implementing:
• Time-bound review of applications
• Allowing increased predictability and transparency of regulatory pathway
• Providing clarity on many complex subjects, including post-trial access
After a series of media allegations of unethical practices, in
2013 the CDSCO office made stricter regulations for
conducting clinical trials
NDCT 2019 by Akash Agnihotri 5
Highlights in the 2019 NDCT
Amendments of drugs and cosmetics rules, 1945:
• Rule 97 includes 122DAA in the drugs and cosmetic rules 1945, which
consists:
Non-application of certain rules for new drugs and investigational new
drugs for human use
Part XA and schedule Y shall not be applicable with regard to new drugs
and investigational new drugs for human use
NDCT 2019 by Akash Agnihotri 6
New Definitions in NDCT Rule 2019
NDCT 2019 by Akash Agnihotri 7
New Definitions: Clinical Trial
• “Clinical trial” in relation to a new drug or investigational new drug means,
any systematic study of such new drug or investigational new drug in
human subjects to generate data for discovering or verifying its:
 Clinical or
 Pharmacological, including pharmacodynamics, pharmacokinetics or
 Adverse effects
• With the objective of determining the safety, efficacy or tolerance of such
new drug or investigational new drug
NDCT 2019 by Akash Agnihotri 8
New Definitions: Academic Clinical Trial
Rule 2(a)
• Clinical trial of a drug already approved for a certain claim
• Initiated by any investigator, academic or research institution
• For a new indication or new route of administration or new dose or new
dosage form
• Results of such a trial are intended to be used only for academic or
research purposes and not for seeking approval of the central licensing
authority or regulatory authority of any country for marketing or
commercial purpose
NDCT 2019 by Akash Agnihotri 9
New Definitions: Biomedical & Health Research
Rule 2(h)
• Research including studies on:
• Basic, applied and operational research
• Clinical research
• Designed primarily to increase scientific knowledge about diseases and
conditions (physical or socio-behavioural) their detection and cause
• Evolving strategies for health promotion, prevention or amelioration of
disease
• Rehabilitation but does not include clinical trial
NDCT 2019 by Akash Agnihotri 10
New Definitions: Biomedical & Health Research
(BHR)
• BHR to be conducted in accordance with “National Ethical Guidelines for
Biomedical and Health Research involving Human Participants” by ICMR
• EC for BHR is required to be registered with DHR, MoH&FW
• Observational & non interventional study of a drug which is not a new
drug, however it is advisable to submit such protocols to CDSCO for
confirmation
NDCT 2019 by Akash Agnihotri 11
New Definitions: Orphan Drugs
Rule X
• Means a drug intended to treat a condition which affects not more than
five lakh persons in India, without any financial gain foreseen by pharma
company but for benefit of humanity
NDCT 2019 by Akash Agnihotri 12
New Definitions: Orphan Drugs
Newly Approved Orphan Drugs
• Approved in 2024:
• Fidanacogene elaparvovec-dzkt (Treatment of adults with moderate to severe
hemophilia B (congenital factor IX deficiency)
• Atidarsagene autotemcel (Treatment of children with pre-symptomatic late
infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early
juvenile (ESEJ) metachromatic leukodystrophy (MLD)
• Approved in 2023:
• Donislecel-jujn (Treatment of adults with Type 1 diabetes who are unable to
approach target HbA1c because of current repeated episodes of severe
hypoglycemia despite intensive diabetes management and education
NDCT 2019 by Akash Agnihotri 13
New Definitions: Orphan Drugs
Top 5 Selling Orphan Drugs in the World (Feb, 2022)
NDCT 2019 by Akash Agnihotri 14
(Ibrutinib)
(Daratumumab
)
(Elexacaftor/
tezacaftor/ivacaftor)
(Emicizumab
)
(Olaprib)
(Drug Name)
New Definitions: Post-Trial Access
Rule CC
Making a new drug or investigational new drug available to a trial
subject after completion of clinical trial through which the said drug
has been found beneficial to a trial subject during clinical trial
NDCT 2019 by Akash Agnihotri 15
New Definitions: New Drug Rule W
NDCT 2019 by Akash Agnihotri 16
Ethics Committee for Clinical Trials
NDCT 2019 by Akash Agnihotri 17
4 pillars of principle of medical ethics
Autonomy: Person’s right to make choices and hold view
Justice: Everyone should be treated equally and benefits are shared
equally
Nonmaleficence (Do not harm): There should be obligations of not
to harm anyone intentionally
Beneficence (Do good): Benefits should be provided to everyone
and one should contribute to the welfare of the society
NDCT 2019 by Akash Agnihotri 18
Ethics Committee Constitution
Ethics
Committee
Members
1 Lay person
1 Women
Member
1 Legal
Expert
1
Independent
Member
1 From Non-
Scientific
Area
1 From
Scientific
Area
1 From
Medical
Field
7 Members Minimum 50% of
members must be
from outside
NDCT 2019 by Akash Agnihotri 19
Ethics Committee for Clinical Trials
• Deals with Regulatory CT as well as Academic CT & BA/BE
• Constitution: Minimum 50% of members must be from outside
• Compensation: Regulatory trial DCGI, Academic trial  guidelines by
ICMR
• Registration with CDSCO: 5 years validity
• Independent ethics committee: According with rule 7,same site/radius of
50 kms
• EC approving BHR,BA/BE, CT  register with CDSCO & DHR
NDCT 2019 by Akash Agnihotri 20
Ethics Committee for Clinical Trials (continued)
Time line
• 60 Days Timeline: Clinical trial as part of discovery, research, manufacture
and marketing
• 90 Days Timeline: For other applications of CT and new drug
• Permission from Central Licensing Authority (CLA) needed
• CLA permission not needed in: Trials solely for academic research
NDCT 2019 by Akash Agnihotri 21
Ethics Committee approval for Clinical Trials
• Multicentric CT: EC approval from each site
• EC not present at site:
• Other site can give approval & bear all responsibilities
• Independent EC approval
• After approval: Inform Central Licensing Authority (CLA) within 15
days
• If rejected and applying to another EC: details of rejection to be submitted
to CLA
NDCT 2019 by Akash Agnihotri 22
Accelerated approval to new drug
• Approval after phase 2 if it shows remarkable efficacy
• For life threatening disease, unmet medical needs
• Surrogate endpoints considered
• Phase 4 CT needed for validation of clinical benefit
NDCT 2019 by Akash Agnihotri 23
Serious Adverse Event (SAE) reporting and
assessment
• A Serious Adverse Event (SAE) is defined as any adverse drug event that is
life threatening or associated with:
• Death
• Inpatient hospitalization
• Prolonged hospitalization
• Persistent or significant disability or incapacity
• A congenital anomaly or birth defect
• Causality assessment: Scales- WHO, Naranjo’s
NDCT 2019 by Akash Agnihotri 24
Timeline for reporting SAE
• Investigator to Sponsor, EC, CDSCO: Initial report < 24 hrs
• Full analyzed report, investigator must submit a report 14 days of
event
• Sponsor must also provide free medical management for the
appropriate time
• Recommendation for compensation:
• Chairperson of Ethics committee to DCGI : <30 calendar days
• Chairperson of Expert committee to DCGI: <60 days of receipt of report
from ethics committee
• Order of compensation from DCGI to Sponsor :<90 days of receipt of
report
• Final compensation paid by sponsor to patient/relative:< 30 days of
receipt of order
NDCT 2019 by Akash Agnihotri 25
Compensation and Formulas
NDCT 2019 by Akash Agnihotri 26
Quantum of compensation and formulas
1. Formula in Case of clinical trial related death:
NDCT 2019 by Akash Agnihotri 27
Quantum of compensation and formulas
2. For permanent disability: Compensation = (DX90XC)/(100X100)
• C= Quantum of compensation in case of death
• D= Percentage of disability
3. SAE causing life-threatening disease: Compensation = N x W
• N=Number of days for life-threatening situation requiring medical care,
irrespective of days of hospitalization
• W=Minimum wage per day of the unskilled worker (in Delhi)
4. Reversible SAE in case it is resolved: Compensation = 2 x W x N
• W = Minimum wage per day of the unskilled worker (in Delhi)
• N = Number of days of hospitalization
NDCT 2019 by Akash Agnihotri 28
Some Important Changes and Alterations
of New Rule
NDCT 2019 by Akash Agnihotri 29
Important Points of NDCT 2019
1. New and Old License Application Fee Structure
Application fees for Phass-1-4 clinical trials now increased up to 6-8 folds
NDCT 2019 by Akash Agnihotri
30
Important Points of NDCT 2019
2. After approval of a Clinical Trial, it is now valid for 2 years from the date of
its approval
3. There are two typed of Ethics Committees (EC):
• One for Clinical Trials & BA/BE studies (Under CDSCO)
• One for Biomedical & Health Research (Under ICMR)
4. The Validity of EC registration is now 5 years
5. DCGI should be informed about the approval granted by the EC within 15
working days of the grant of such approval
NDCT 2019 by Akash Agnihotri 31
Important Points of NDCT 2019
6. In case of rejection of trial application, the applicant may request to
reconsider the application within a period of 60 days from the date of
rejection of the application.
7. A 6 monthly report of clinical trial should be submitted to DCGI through
SUGAM portal. But enrollment status should be submitted to DCGI every
3 months.
8. The termination of the clinical trial and BA/BE study should be notified to
CLA within 30 days with detail of its cause for termination.
NDCT 2019 by Akash Agnihotri 32
Important Points of NDCT 2019
9. Post-trial access of drug to the patients (should be provided by the
sponsor at free-of-cost to the trial subject after the trial is over), which
completely depends on recommendation of the investigator and its
approval by EC.
10. For conducting an academic clinical trial (intended solely for academic
research purposes) only Ethics Committee approval is mandatory (no
permission is required from DCGI) and such clinical trial should not used
for promotional or approval purposes.
NDCT 2019 by Akash Agnihotri 33
Important Points of NDCT 2019
11. The Sponsor should provide free medical management to the “subject as
long as required as per the opinion of investigator, or till such time it is
established that the injury is not related to” the clinical trial or BA/BE
study.
12. “ The sponsor or its representative and the investigator shall forward their
reports on Serous Adverse Events (SAE) of death after due analysis” to
DCGI, HOI, Chairperson of EC within 14 days of the “Knowledge of
occurrence of SAE of death”
NDCT 2019 by Akash Agnihotri 34
Important Points of NDCT 2019
13. Periodic Safety Update Report (PSUR): Timeline is reserved as per old
regulation but content & structure is now should be arranged with very
detailed and exhaustive EU PBRER (ICH) format.
EU PBRER: European Union Periodic Benefit Risk Evaluation Report
NDCT 2019 by Akash Agnihotri 35
As per the Drugs and Cosmetics Act, 1940 & Rules, 1945 including
NDCT Rules, 2019
PSURs are required to be submitted every six months for first two
years from the date of approval and for subsequent two years
annually
Overall comparison of new rules with former
rules
NDCT 2019 by Akash Agnihotri
36
Overall comparison of new rules with former rules
NDCT 2019 by Akash
Agnihotri
37
Overall comparison of new rules with former rules
NDCT 2019 by Akash Agnihotri 38
Overall comparison of new rules with former rules
NDCT 2019 by Akash
Agnihotri 39
Overall comparison of new rules with former rules
NDCT 2019 by
Akash Agnihotri
40
Overall comparison of new rules with former rules
NDCT 2019 by Akash
Agnihotri
41
Overall comparison of new rules with former rules
NDCT 2019 by Akash Agnihotri 42
Overall comparison of new rules with former rules
NDCT 2019 by Akash Agnihotri
43
Overall comparison of new rules with former rules
NDCT 2019
by Akash
Agnihotri
44
Overall comparison of new rules with former rules
NDCT 2019
by Akash
Agnihotri
45
Flow chart on the
compensation
procedures in case
of serious adverse
events and death
during the clinical
trials
NDCT 2019 by Akash Agnihotri 46
Flow chart on the
compensation
procedures in case
of serious adverse
events and death
during the clinical
trials
NDCT 2019 by Akash Agnihotri 47
Flow chart on
general
procedure of
grant of
approval to
conduct clinical
trials in India
NDCT 2019 by Akash Agnihotri
48
References
I. Dubey A, Kotian B, Ravi GS. New Drugs and Clinical Trials Rules, 2019: Towards Fast-track
Accessibility of New Drugs to the Indian Population. Indian J of Pharmaceutical Education and
Research. 2019;53(4s):s451-s459.
II. NDCT Rule 2019. Accessed by: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-
documents/NewDrugs_CTRules_2019.pdf
III. Singh N, Madkaikar NJ, Gokhale PM, Parmar DV. New drugs and clinical trials rules 2019:
Changes in responsibilities of the ethics committee. Perspect Clin Res. 2020 Jan-Mar;11(1):37-
43. doi: 10.4103/picr.PICR_208_19. Epub 2020 Jan 31. PMID: 32154148; PMCID:
PMC7034142.
IV. Annapurna SA, Rao SY. New drug and clinical trial rules, 2019: an overview. Int J Clin Trials
2020;7(4):278-84.
V. Urooj M, Husain GM, Khan MA, Kazmi MH. Compensation to clinical trial participants in India:
A gap analysis. Int J Pharm Investig. 2017 Apr-Jun;7(2):41-46. doi: 10.4103/jphi.JPHI_31_17.
PMID: 28929045; PMCID: PMC5553263.
VI. Postgraduate Pharmacology by Sougata Sarkar, Paras Medical Publisher, 2020.
VII. Orphan Drug Report 2022, by By Melanie Senior and Andreas Hadjivasiliou, April 2022
NDCT 2019 by Akash Agnihotri 49
MCQs on NDCT 2019
NDCT 2019 by Akash Agnihotri 50
MCQ No. 01
The renewal of the ethics committee must be
completed ____________
NDCT 2019 by Akash Agnihotri 51
a) 60 days before the expiry of the license
b) 90 days prior to the expiry of the license
c) 30 days before the expiry of the license
d) 120 days prior to the expiry of the license
MCQ No. 02
The validity period of Ethics Committee
registration is ____________
NDCT 2019 by Akash Agnihotri 52
a) 1 Year
b) 3 Years
c) 5 Years
d) 10 Years
MCQ No. 03
In cases where patients have an expected mortality
of 90% or more within 30 days, the quantum of
compensation should be:
NDCT 2019 by Akash Agnihotri 53
a) ₹ 1 Lakh
b) ₹ 2 Lakh
c) ₹ 5 Lakh
d) ₹ 10 Lakh
MCQ No. 04
Before initiating a study involving primary data collection,
the Principal Investigator must ensure that various
approvals are obtained. Which of the following approvals is
absolutely mandatory?
NDCT 2019 by Akash Agnihotri 54
a) Scientific committee approval
b) Ethics committee approval
c) Technical committee approval
d) Regulatory authority approval
MCQ No. 05
According to the timeline for reporting Serious Adverse
Events (SAEs) and the order of compensation from DCGI
to the Sponsor, the compensation order should be issued:
NDCT 2019 by Akash Agnihotri 55
a) Within 30 days of receipt of the SAE report
b) Within 60 days of receipt of the SAE report
c) Within 90 days of receipt of the SAE report
d) Within 120 days of receipt of the SAE report
MCQ’s Answer Key
NDCT 2019 by Akash Agnihotri 56
1. b) 90 days prior to the expiry of the license
2. c) 5 Years
3. b) 2 Lakh
4. b) Ethics Committee Approval
5. c) Within 90 days of receipt of the SAE report
Thank you
NDCT 2019 by Akash Agnihotri 57

More Related Content

What's hot

Patient medication adherence
Patient medication adherencePatient medication adherence
Patient medication adherence
Rana Pelluri
 
Top 52 clinical research associate interview questions and answers pdf
Top 52 clinical research associate interview questions and answers pdfTop 52 clinical research associate interview questions and answers pdf
Top 52 clinical research associate interview questions and answers pdf
HarrisonFord888
 
NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)
Suvarta Maru
 
Abbreviated new drug application submission
Abbreviated new drug application submissionAbbreviated new drug application submission
Abbreviated new drug application submission
Gaurav Sharma
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
Kirsha K S
 
Poison information center
Poison information centerPoison information center
Poison information center
Sri Ramachandra University
 
Compensation given in clinical trial
Compensation given in clinical trialCompensation given in clinical trial
Compensation given in clinical trial
Neha Singh
 
Drug development process.
Drug development process.Drug development process.
Drug development process.
Akhil Joseph
 
Prescribed medication order & Communication Skills for Pharmacist
Prescribed medication order & Communication Skills for PharmacistPrescribed medication order & Communication Skills for Pharmacist
Prescribed medication order & Communication Skills for Pharmacist
Dr Manish Pal Singh
 
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETINDRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
SHIVANEE VYAS
 
Hospital pharmacy and its organization Sneha Patel
Hospital pharmacy and its organization Sneha PatelHospital pharmacy and its organization Sneha Patel
Hospital pharmacy and its organization Sneha Patel
Sneha Patel
 
Patients medication history interview
Patients medication history interviewPatients medication history interview
Patients medication history interview
Subhash Yende
 
Validation
ValidationValidation
Validation
Hannah Oluyemi
 
Fast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalFast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and Approval
Debashish Sarkar
 
Ward round participation
Ward round participationWard round participation
Ward round participation
Dr. Ramesh Bhandari
 
Markov model
Markov modelMarkov model
Reporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacistReporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacist
Dr. Ramesh Bhandari
 
A Brief Guide to the FDA Drug Approval Process
A Brief Guide to the FDA Drug Approval ProcessA Brief Guide to the FDA Drug Approval Process
A Brief Guide to the FDA Drug Approval Process
Perficient
 
Preclinical trials
Preclinical trialsPreclinical trials
Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )
Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )
Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )
JAYACHANDRA AKUTHOTA
 

What's hot (20)

Patient medication adherence
Patient medication adherencePatient medication adherence
Patient medication adherence
 
Top 52 clinical research associate interview questions and answers pdf
Top 52 clinical research associate interview questions and answers pdfTop 52 clinical research associate interview questions and answers pdf
Top 52 clinical research associate interview questions and answers pdf
 
NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)NEW DRUG APPLICATION ( NDA)
NEW DRUG APPLICATION ( NDA)
 
Abbreviated new drug application submission
Abbreviated new drug application submissionAbbreviated new drug application submission
Abbreviated new drug application submission
 
Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
 
Poison information center
Poison information centerPoison information center
Poison information center
 
Compensation given in clinical trial
Compensation given in clinical trialCompensation given in clinical trial
Compensation given in clinical trial
 
Drug development process.
Drug development process.Drug development process.
Drug development process.
 
Prescribed medication order & Communication Skills for Pharmacist
Prescribed medication order & Communication Skills for PharmacistPrescribed medication order & Communication Skills for Pharmacist
Prescribed medication order & Communication Skills for Pharmacist
 
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETINDRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
DRUG INFORMATION SERVICE AND DRUG INFORMATION BULLETIN
 
Hospital pharmacy and its organization Sneha Patel
Hospital pharmacy and its organization Sneha PatelHospital pharmacy and its organization Sneha Patel
Hospital pharmacy and its organization Sneha Patel
 
Patients medication history interview
Patients medication history interviewPatients medication history interview
Patients medication history interview
 
Validation
ValidationValidation
Validation
 
Fast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and ApprovalFast track drugs - Rapid study and Approval
Fast track drugs - Rapid study and Approval
 
Ward round participation
Ward round participationWard round participation
Ward round participation
 
Markov model
Markov modelMarkov model
Markov model
 
Reporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacistReporting of pharmacovigilance and role of pharmacist
Reporting of pharmacovigilance and role of pharmacist
 
A Brief Guide to the FDA Drug Approval Process
A Brief Guide to the FDA Drug Approval ProcessA Brief Guide to the FDA Drug Approval Process
A Brief Guide to the FDA Drug Approval Process
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trials
 
Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )
Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )
Indian regulatory requirements- CDSCO ( IP-2 / UNIT 5 )
 

Similar to NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019

New drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdfNew drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdf
crazyboy92
 
Ndct rule 2019 (manisha)
Ndct rule 2019 (manisha)Ndct rule 2019 (manisha)
Ndct rule 2019 (manisha)
ManishaChauhan86
 
Example of E-poster on Current Regulations for Conducting Clinical Trials in...
Example of E-poster  on Current Regulations for Conducting Clinical Trials in...Example of E-poster  on Current Regulations for Conducting Clinical Trials in...
Example of E-poster on Current Regulations for Conducting Clinical Trials in...
VasundhraKakkar
 
Clinical trial regulation 2019
Clinical trial regulation 2019Clinical trial regulation 2019
Clinical trial regulation 2019
swathijai
 
Requirement to clinical study
Requirement to clinical studyRequirement to clinical study
Requirement to clinical study
DhanshreeBhattad
 
Clinical trials legal issues
Clinical trials   legal issuesClinical trials   legal issues
Clinical trials legal issues
Upendra Rangavajjula
 
crppt-230616130903-db08806976537846262.pdf
crppt-230616130903-db08806976537846262.pdfcrppt-230616130903-db08806976537846262.pdf
crppt-230616130903-db08806976537846262.pdf
mehulsarathy
 
Introduction to Clinical Research Regulations
Introduction to Clinical Research RegulationsIntroduction to Clinical Research Regulations
Introduction to Clinical Research Regulations
ClinosolIndia
 
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.pptDr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
RRahulMehrotrra1
 
Regulatory Procedures
Regulatory ProceduresRegulatory Procedures
Regulatory Procedures
EURORDIS Rare Diseases Europe
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
Nikhat Sheikh
 
Schedule y
Schedule  ySchedule  y
Schedule y
kumargourav40
 
schedule y
schedule yschedule y
schedule y
Rohit K.
 
Schedule y under drugs and cosmetic act 1945
Schedule y  under drugs and cosmetic act 1945Schedule y  under drugs and cosmetic act 1945
Schedule y under drugs and cosmetic act 1945
neelotpal31
 
clinical trial Management with ethics committee
clinical trial  Management with ethics committeeclinical trial  Management with ethics committee
clinical trial Management with ethics committee
SrinivasanBB
 
Cdsco- a regulatory overview
Cdsco- a regulatory overviewCdsco- a regulatory overview
Cdsco- a regulatory overview
Vivekanandan S
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Dr. Tayaba Khan
 
Drug approval process
Drug approval processDrug approval process
Drug approval process
LitashaGandhi
 
Nw biotech fundamentals day 1 session 3 regulatory
Nw biotech fundamentals day 1 session 3   regulatoryNw biotech fundamentals day 1 session 3   regulatory
Nw biotech fundamentals day 1 session 3 regulatory
Nicholas Weston Lawyers
 
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
DrSivakumarSelvaraj
 

Similar to NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019 (20)

New drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdfNew drugs and clinical trial rules 2019.pdf
New drugs and clinical trial rules 2019.pdf
 
Ndct rule 2019 (manisha)
Ndct rule 2019 (manisha)Ndct rule 2019 (manisha)
Ndct rule 2019 (manisha)
 
Example of E-poster on Current Regulations for Conducting Clinical Trials in...
Example of E-poster  on Current Regulations for Conducting Clinical Trials in...Example of E-poster  on Current Regulations for Conducting Clinical Trials in...
Example of E-poster on Current Regulations for Conducting Clinical Trials in...
 
Clinical trial regulation 2019
Clinical trial regulation 2019Clinical trial regulation 2019
Clinical trial regulation 2019
 
Requirement to clinical study
Requirement to clinical studyRequirement to clinical study
Requirement to clinical study
 
Clinical trials legal issues
Clinical trials   legal issuesClinical trials   legal issues
Clinical trials legal issues
 
crppt-230616130903-db08806976537846262.pdf
crppt-230616130903-db08806976537846262.pdfcrppt-230616130903-db08806976537846262.pdf
crppt-230616130903-db08806976537846262.pdf
 
Introduction to Clinical Research Regulations
Introduction to Clinical Research RegulationsIntroduction to Clinical Research Regulations
Introduction to Clinical Research Regulations
 
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.pptDr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
Dr_Prabhat_Roy_Kumar_CT_regulatory_challnages_in_India__19Nov14__revised.ppt
 
Regulatory Procedures
Regulatory ProceduresRegulatory Procedures
Regulatory Procedures
 
Cdsco ppt
Cdsco pptCdsco ppt
Cdsco ppt
 
Schedule y
Schedule  ySchedule  y
Schedule y
 
schedule y
schedule yschedule y
schedule y
 
Schedule y under drugs and cosmetic act 1945
Schedule y  under drugs and cosmetic act 1945Schedule y  under drugs and cosmetic act 1945
Schedule y under drugs and cosmetic act 1945
 
clinical trial Management with ethics committee
clinical trial  Management with ethics committeeclinical trial  Management with ethics committee
clinical trial Management with ethics committee
 
Cdsco- a regulatory overview
Cdsco- a regulatory overviewCdsco- a regulatory overview
Cdsco- a regulatory overview
 
Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...Health Technology Assessment: Comparison between UK and Canada Processes by D...
Health Technology Assessment: Comparison between UK and Canada Processes by D...
 
Drug approval process
Drug approval processDrug approval process
Drug approval process
 
Nw biotech fundamentals day 1 session 3 regulatory
Nw biotech fundamentals day 1 session 3   regulatoryNw biotech fundamentals day 1 session 3   regulatory
Nw biotech fundamentals day 1 session 3 regulatory
 
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
2. 신규 체외진단법 도입에 따른 의료기기산업에 미치는 영향.pptx
 

More from Akash Agnihotri

10 Concepts that explains the modern world
10 Concepts that explains the modern world10 Concepts that explains the modern world
10 Concepts that explains the modern world
Akash Agnihotri
 
Pharmacodynamics of Drugs: Introduction to Pharmacology
Pharmacodynamics of Drugs: Introduction to PharmacologyPharmacodynamics of Drugs: Introduction to Pharmacology
Pharmacodynamics of Drugs: Introduction to Pharmacology
Akash Agnihotri
 
Pharmacokinetics of Drugs: Introduction to Pharmacology
Pharmacokinetics of Drugs: Introduction to PharmacologyPharmacokinetics of Drugs: Introduction to Pharmacology
Pharmacokinetics of Drugs: Introduction to Pharmacology
Akash Agnihotri
 
Receptor desensitization and regulation of receptors, Diseases resulting from...
Receptor desensitization and regulation of receptors,Diseases resulting from...Receptor desensitization and regulation of receptors,Diseases resulting from...
Receptor desensitization and regulation of receptors, Diseases resulting from...
Akash Agnihotri
 
Safety pharmacology and clinical trials
Safety pharmacology and clinical trialsSafety pharmacology and clinical trials
Safety pharmacology and clinical trials
Akash Agnihotri
 
Drugs used in Heart Failure
Drugs used in Heart FailureDrugs used in Heart Failure
Drugs used in Heart Failure
Akash Agnihotri
 
Histamine,Serotonin and ergot alkaloids
Histamine,Serotonin and ergot alkaloidsHistamine,Serotonin and ergot alkaloids
Histamine,Serotonin and ergot alkaloids
Akash Agnihotri
 
New Drugs Approved by FDA in August-September 2022 by DrugsInfo
New Drugs Approved by FDA in August-September 2022 by DrugsInfoNew Drugs Approved by FDA in August-September 2022 by DrugsInfo
New Drugs Approved by FDA in August-September 2022 by DrugsInfo
Akash Agnihotri
 
National List of Essential Meidicne 2022 by DrugsInfo
National List of Essential Meidicne 2022 by DrugsInfoNational List of Essential Meidicne 2022 by DrugsInfo
National List of Essential Meidicne 2022 by DrugsInfo
Akash Agnihotri
 
Caffeine-Pharmacology and other info by DrugsInfo
Caffeine-Pharmacology and other info by DrugsInfoCaffeine-Pharmacology and other info by DrugsInfo
Caffeine-Pharmacology and other info by DrugsInfo
Akash Agnihotri
 
Animal models for screening agents useful in Heart Failure
Animal models for screening agents useful in Heart FailureAnimal models for screening agents useful in Heart Failure
Animal models for screening agents useful in Heart Failure
Akash Agnihotri
 
Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...
Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...
Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...
Akash Agnihotri
 
Functional Organization of Autonomic Activity
Functional Organization of Autonomic ActivityFunctional Organization of Autonomic Activity
Functional Organization of Autonomic Activity
Akash Agnihotri
 
Transporter superfamilies in the human genome
Transporter superfamilies in the human genomeTransporter superfamilies in the human genome
Transporter superfamilies in the human genome
Akash Agnihotri
 
Basic Mechanisms of Membrane Transport
Basic Mechanisms of Membrane TransportBasic Mechanisms of Membrane Transport
Basic Mechanisms of Membrane Transport
Akash Agnihotri
 
Absorption- Extent and Rate
Absorption- Extent and RateAbsorption- Extent and Rate
Absorption- Extent and Rate
Akash Agnihotri
 
Distribution of Drugs
Distribution of DrugsDistribution of Drugs
Distribution of Drugs
Akash Agnihotri
 
Recent Advances in pharmacotherapy of Respiratory Disorders
Recent Advances in pharmacotherapy of Respiratory DisordersRecent Advances in pharmacotherapy of Respiratory Disorders
Recent Advances in pharmacotherapy of Respiratory Disorders
Akash Agnihotri
 

More from Akash Agnihotri (18)

10 Concepts that explains the modern world
10 Concepts that explains the modern world10 Concepts that explains the modern world
10 Concepts that explains the modern world
 
Pharmacodynamics of Drugs: Introduction to Pharmacology
Pharmacodynamics of Drugs: Introduction to PharmacologyPharmacodynamics of Drugs: Introduction to Pharmacology
Pharmacodynamics of Drugs: Introduction to Pharmacology
 
Pharmacokinetics of Drugs: Introduction to Pharmacology
Pharmacokinetics of Drugs: Introduction to PharmacologyPharmacokinetics of Drugs: Introduction to Pharmacology
Pharmacokinetics of Drugs: Introduction to Pharmacology
 
Receptor desensitization and regulation of receptors, Diseases resulting from...
Receptor desensitization and regulation of receptors,Diseases resulting from...Receptor desensitization and regulation of receptors,Diseases resulting from...
Receptor desensitization and regulation of receptors, Diseases resulting from...
 
Safety pharmacology and clinical trials
Safety pharmacology and clinical trialsSafety pharmacology and clinical trials
Safety pharmacology and clinical trials
 
Drugs used in Heart Failure
Drugs used in Heart FailureDrugs used in Heart Failure
Drugs used in Heart Failure
 
Histamine,Serotonin and ergot alkaloids
Histamine,Serotonin and ergot alkaloidsHistamine,Serotonin and ergot alkaloids
Histamine,Serotonin and ergot alkaloids
 
New Drugs Approved by FDA in August-September 2022 by DrugsInfo
New Drugs Approved by FDA in August-September 2022 by DrugsInfoNew Drugs Approved by FDA in August-September 2022 by DrugsInfo
New Drugs Approved by FDA in August-September 2022 by DrugsInfo
 
National List of Essential Meidicne 2022 by DrugsInfo
National List of Essential Meidicne 2022 by DrugsInfoNational List of Essential Meidicne 2022 by DrugsInfo
National List of Essential Meidicne 2022 by DrugsInfo
 
Caffeine-Pharmacology and other info by DrugsInfo
Caffeine-Pharmacology and other info by DrugsInfoCaffeine-Pharmacology and other info by DrugsInfo
Caffeine-Pharmacology and other info by DrugsInfo
 
Animal models for screening agents useful in Heart Failure
Animal models for screening agents useful in Heart FailureAnimal models for screening agents useful in Heart Failure
Animal models for screening agents useful in Heart Failure
 
Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...
Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...
Adrenoceptors Agonists & Sympathomimetic Drugs (Autonomic Nervous System) (Ph...
 
Functional Organization of Autonomic Activity
Functional Organization of Autonomic ActivityFunctional Organization of Autonomic Activity
Functional Organization of Autonomic Activity
 
Transporter superfamilies in the human genome
Transporter superfamilies in the human genomeTransporter superfamilies in the human genome
Transporter superfamilies in the human genome
 
Basic Mechanisms of Membrane Transport
Basic Mechanisms of Membrane TransportBasic Mechanisms of Membrane Transport
Basic Mechanisms of Membrane Transport
 
Absorption- Extent and Rate
Absorption- Extent and RateAbsorption- Extent and Rate
Absorption- Extent and Rate
 
Distribution of Drugs
Distribution of DrugsDistribution of Drugs
Distribution of Drugs
 
Recent Advances in pharmacotherapy of Respiratory Disorders
Recent Advances in pharmacotherapy of Respiratory DisordersRecent Advances in pharmacotherapy of Respiratory Disorders
Recent Advances in pharmacotherapy of Respiratory Disorders
 

Recently uploaded

Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
arahmanzai5
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
rishi2789
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
walterHu5
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
Swastik Ayurveda
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
rightmanforbloodline
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
HongBiThi1
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
NephroTube - Dr.Gawad
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
Swastik Ayurveda
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
Dr. Jyothirmai Paindla
 

Recently uploaded (20)

Diabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatmentDiabetic nephropathy diagnosis treatment
Diabetic nephropathy diagnosis treatment
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdfCHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
CHEMOTHERAPY_RDP_CHAPTER 3_ANTIFUNGAL AGENT.pdf
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxDoes Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
 
Best Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and IndigestionBest Ayurvedic medicine for Gas and Indigestion
Best Ayurvedic medicine for Gas and Indigestion
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấuK CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
K CỔ TỬ CUNG.pdf tự ghi chép, chữ hơi xấu
 
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.GawadHemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 
The Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in IndiaThe Best Ayurvedic Antacid Tablets in India
The Best Ayurvedic Antacid Tablets in India
 
Journal Article Review on Rasamanikya
Journal Article Review on RasamanikyaJournal Article Review on Rasamanikya
Journal Article Review on Rasamanikya
 

NDCT Rules, 2019: An Overview | New Drugs and Clinical Trial Rules 2019

  • 1. New Drugs and Clinical Trials (NDCT) rules, 2019 An Overview Akash Agnihotri Tutor Department of Pharmacology Amrita School of Medicine, Faridabad NDCT 2019 by Akash Agnihotri 1
  • 2. NDCT 2019 • Draft copies of new clinical trials rules on public domain: 7th February, 2018 • Objections and suggestions invited from all stakeholders • Central Government notified “New Drugs and Clinical Trials Rules, 2019” on 19th Mar 2019 • New Drug and Clinical Trial Rules, 2019 are applicable from 19th Mar 2019, except Chapter 4 [Ethics Committee for Biomedical and Health Research], which came into force after 180 days (i.e. 21st Sep 2019) 2 NDCT 2019 by Akash Agnihotri
  • 3. The New Drugs & Clinical Trial Rules, 2019 New rules are structured around: • 13 chapters, which includes 107 rules and 8 schedules Will apply to: • All new drugs • Investigational new drugs • Clinical trials • Biomedical and health research • Ethics committees 3 NDCT 2019 by Akash Agnihotri
  • 4. The New Drugs & Clinical Trial Rules, 2019 New rules override part XA and Schedule Y of medicine and cosmetics rules, 1945 Earlier regulations and schedule Y will still be applicable for veterinary use drugs 4 NDCT 2019 by Akash Agnihotri Schedule Y was a law that outlined the requirements and guidelines for conducting clinical trials and importing or manufacturing new drugs in India Part XA As per Drugs and cosmetic Rules 1945, part X-A, import or manufacture of new drug for clinical trials or marketing
  • 5. NDCT 2019, Aimed Promoting clinical research within the country by implementing: • Time-bound review of applications • Allowing increased predictability and transparency of regulatory pathway • Providing clarity on many complex subjects, including post-trial access After a series of media allegations of unethical practices, in 2013 the CDSCO office made stricter regulations for conducting clinical trials NDCT 2019 by Akash Agnihotri 5
  • 6. Highlights in the 2019 NDCT Amendments of drugs and cosmetics rules, 1945: • Rule 97 includes 122DAA in the drugs and cosmetic rules 1945, which consists: Non-application of certain rules for new drugs and investigational new drugs for human use Part XA and schedule Y shall not be applicable with regard to new drugs and investigational new drugs for human use NDCT 2019 by Akash Agnihotri 6
  • 7. New Definitions in NDCT Rule 2019 NDCT 2019 by Akash Agnihotri 7
  • 8. New Definitions: Clinical Trial • “Clinical trial” in relation to a new drug or investigational new drug means, any systematic study of such new drug or investigational new drug in human subjects to generate data for discovering or verifying its:  Clinical or  Pharmacological, including pharmacodynamics, pharmacokinetics or  Adverse effects • With the objective of determining the safety, efficacy or tolerance of such new drug or investigational new drug NDCT 2019 by Akash Agnihotri 8
  • 9. New Definitions: Academic Clinical Trial Rule 2(a) • Clinical trial of a drug already approved for a certain claim • Initiated by any investigator, academic or research institution • For a new indication or new route of administration or new dose or new dosage form • Results of such a trial are intended to be used only for academic or research purposes and not for seeking approval of the central licensing authority or regulatory authority of any country for marketing or commercial purpose NDCT 2019 by Akash Agnihotri 9
  • 10. New Definitions: Biomedical & Health Research Rule 2(h) • Research including studies on: • Basic, applied and operational research • Clinical research • Designed primarily to increase scientific knowledge about diseases and conditions (physical or socio-behavioural) their detection and cause • Evolving strategies for health promotion, prevention or amelioration of disease • Rehabilitation but does not include clinical trial NDCT 2019 by Akash Agnihotri 10
  • 11. New Definitions: Biomedical & Health Research (BHR) • BHR to be conducted in accordance with “National Ethical Guidelines for Biomedical and Health Research involving Human Participants” by ICMR • EC for BHR is required to be registered with DHR, MoH&FW • Observational & non interventional study of a drug which is not a new drug, however it is advisable to submit such protocols to CDSCO for confirmation NDCT 2019 by Akash Agnihotri 11
  • 12. New Definitions: Orphan Drugs Rule X • Means a drug intended to treat a condition which affects not more than five lakh persons in India, without any financial gain foreseen by pharma company but for benefit of humanity NDCT 2019 by Akash Agnihotri 12
  • 13. New Definitions: Orphan Drugs Newly Approved Orphan Drugs • Approved in 2024: • Fidanacogene elaparvovec-dzkt (Treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) • Atidarsagene autotemcel (Treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD) • Approved in 2023: • Donislecel-jujn (Treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education NDCT 2019 by Akash Agnihotri 13
  • 14. New Definitions: Orphan Drugs Top 5 Selling Orphan Drugs in the World (Feb, 2022) NDCT 2019 by Akash Agnihotri 14 (Ibrutinib) (Daratumumab ) (Elexacaftor/ tezacaftor/ivacaftor) (Emicizumab ) (Olaprib) (Drug Name)
  • 15. New Definitions: Post-Trial Access Rule CC Making a new drug or investigational new drug available to a trial subject after completion of clinical trial through which the said drug has been found beneficial to a trial subject during clinical trial NDCT 2019 by Akash Agnihotri 15
  • 16. New Definitions: New Drug Rule W NDCT 2019 by Akash Agnihotri 16
  • 17. Ethics Committee for Clinical Trials NDCT 2019 by Akash Agnihotri 17
  • 18. 4 pillars of principle of medical ethics Autonomy: Person’s right to make choices and hold view Justice: Everyone should be treated equally and benefits are shared equally Nonmaleficence (Do not harm): There should be obligations of not to harm anyone intentionally Beneficence (Do good): Benefits should be provided to everyone and one should contribute to the welfare of the society NDCT 2019 by Akash Agnihotri 18
  • 19. Ethics Committee Constitution Ethics Committee Members 1 Lay person 1 Women Member 1 Legal Expert 1 Independent Member 1 From Non- Scientific Area 1 From Scientific Area 1 From Medical Field 7 Members Minimum 50% of members must be from outside NDCT 2019 by Akash Agnihotri 19
  • 20. Ethics Committee for Clinical Trials • Deals with Regulatory CT as well as Academic CT & BA/BE • Constitution: Minimum 50% of members must be from outside • Compensation: Regulatory trial DCGI, Academic trial  guidelines by ICMR • Registration with CDSCO: 5 years validity • Independent ethics committee: According with rule 7,same site/radius of 50 kms • EC approving BHR,BA/BE, CT  register with CDSCO & DHR NDCT 2019 by Akash Agnihotri 20
  • 21. Ethics Committee for Clinical Trials (continued) Time line • 60 Days Timeline: Clinical trial as part of discovery, research, manufacture and marketing • 90 Days Timeline: For other applications of CT and new drug • Permission from Central Licensing Authority (CLA) needed • CLA permission not needed in: Trials solely for academic research NDCT 2019 by Akash Agnihotri 21
  • 22. Ethics Committee approval for Clinical Trials • Multicentric CT: EC approval from each site • EC not present at site: • Other site can give approval & bear all responsibilities • Independent EC approval • After approval: Inform Central Licensing Authority (CLA) within 15 days • If rejected and applying to another EC: details of rejection to be submitted to CLA NDCT 2019 by Akash Agnihotri 22
  • 23. Accelerated approval to new drug • Approval after phase 2 if it shows remarkable efficacy • For life threatening disease, unmet medical needs • Surrogate endpoints considered • Phase 4 CT needed for validation of clinical benefit NDCT 2019 by Akash Agnihotri 23
  • 24. Serious Adverse Event (SAE) reporting and assessment • A Serious Adverse Event (SAE) is defined as any adverse drug event that is life threatening or associated with: • Death • Inpatient hospitalization • Prolonged hospitalization • Persistent or significant disability or incapacity • A congenital anomaly or birth defect • Causality assessment: Scales- WHO, Naranjo’s NDCT 2019 by Akash Agnihotri 24
  • 25. Timeline for reporting SAE • Investigator to Sponsor, EC, CDSCO: Initial report < 24 hrs • Full analyzed report, investigator must submit a report 14 days of event • Sponsor must also provide free medical management for the appropriate time • Recommendation for compensation: • Chairperson of Ethics committee to DCGI : <30 calendar days • Chairperson of Expert committee to DCGI: <60 days of receipt of report from ethics committee • Order of compensation from DCGI to Sponsor :<90 days of receipt of report • Final compensation paid by sponsor to patient/relative:< 30 days of receipt of order NDCT 2019 by Akash Agnihotri 25
  • 26. Compensation and Formulas NDCT 2019 by Akash Agnihotri 26
  • 27. Quantum of compensation and formulas 1. Formula in Case of clinical trial related death: NDCT 2019 by Akash Agnihotri 27
  • 28. Quantum of compensation and formulas 2. For permanent disability: Compensation = (DX90XC)/(100X100) • C= Quantum of compensation in case of death • D= Percentage of disability 3. SAE causing life-threatening disease: Compensation = N x W • N=Number of days for life-threatening situation requiring medical care, irrespective of days of hospitalization • W=Minimum wage per day of the unskilled worker (in Delhi) 4. Reversible SAE in case it is resolved: Compensation = 2 x W x N • W = Minimum wage per day of the unskilled worker (in Delhi) • N = Number of days of hospitalization NDCT 2019 by Akash Agnihotri 28
  • 29. Some Important Changes and Alterations of New Rule NDCT 2019 by Akash Agnihotri 29
  • 30. Important Points of NDCT 2019 1. New and Old License Application Fee Structure Application fees for Phass-1-4 clinical trials now increased up to 6-8 folds NDCT 2019 by Akash Agnihotri 30
  • 31. Important Points of NDCT 2019 2. After approval of a Clinical Trial, it is now valid for 2 years from the date of its approval 3. There are two typed of Ethics Committees (EC): • One for Clinical Trials & BA/BE studies (Under CDSCO) • One for Biomedical & Health Research (Under ICMR) 4. The Validity of EC registration is now 5 years 5. DCGI should be informed about the approval granted by the EC within 15 working days of the grant of such approval NDCT 2019 by Akash Agnihotri 31
  • 32. Important Points of NDCT 2019 6. In case of rejection of trial application, the applicant may request to reconsider the application within a period of 60 days from the date of rejection of the application. 7. A 6 monthly report of clinical trial should be submitted to DCGI through SUGAM portal. But enrollment status should be submitted to DCGI every 3 months. 8. The termination of the clinical trial and BA/BE study should be notified to CLA within 30 days with detail of its cause for termination. NDCT 2019 by Akash Agnihotri 32
  • 33. Important Points of NDCT 2019 9. Post-trial access of drug to the patients (should be provided by the sponsor at free-of-cost to the trial subject after the trial is over), which completely depends on recommendation of the investigator and its approval by EC. 10. For conducting an academic clinical trial (intended solely for academic research purposes) only Ethics Committee approval is mandatory (no permission is required from DCGI) and such clinical trial should not used for promotional or approval purposes. NDCT 2019 by Akash Agnihotri 33
  • 34. Important Points of NDCT 2019 11. The Sponsor should provide free medical management to the “subject as long as required as per the opinion of investigator, or till such time it is established that the injury is not related to” the clinical trial or BA/BE study. 12. “ The sponsor or its representative and the investigator shall forward their reports on Serous Adverse Events (SAE) of death after due analysis” to DCGI, HOI, Chairperson of EC within 14 days of the “Knowledge of occurrence of SAE of death” NDCT 2019 by Akash Agnihotri 34
  • 35. Important Points of NDCT 2019 13. Periodic Safety Update Report (PSUR): Timeline is reserved as per old regulation but content & structure is now should be arranged with very detailed and exhaustive EU PBRER (ICH) format. EU PBRER: European Union Periodic Benefit Risk Evaluation Report NDCT 2019 by Akash Agnihotri 35 As per the Drugs and Cosmetics Act, 1940 & Rules, 1945 including NDCT Rules, 2019 PSURs are required to be submitted every six months for first two years from the date of approval and for subsequent two years annually
  • 36. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 36
  • 37. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 37
  • 38. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 38
  • 39. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 39
  • 40. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 40
  • 41. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 41
  • 42. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 42
  • 43. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 43
  • 44. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 44
  • 45. Overall comparison of new rules with former rules NDCT 2019 by Akash Agnihotri 45
  • 46. Flow chart on the compensation procedures in case of serious adverse events and death during the clinical trials NDCT 2019 by Akash Agnihotri 46
  • 47. Flow chart on the compensation procedures in case of serious adverse events and death during the clinical trials NDCT 2019 by Akash Agnihotri 47
  • 48. Flow chart on general procedure of grant of approval to conduct clinical trials in India NDCT 2019 by Akash Agnihotri 48
  • 49. References I. Dubey A, Kotian B, Ravi GS. New Drugs and Clinical Trials Rules, 2019: Towards Fast-track Accessibility of New Drugs to the Indian Population. Indian J of Pharmaceutical Education and Research. 2019;53(4s):s451-s459. II. NDCT Rule 2019. Accessed by: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf- documents/NewDrugs_CTRules_2019.pdf III. Singh N, Madkaikar NJ, Gokhale PM, Parmar DV. New drugs and clinical trials rules 2019: Changes in responsibilities of the ethics committee. Perspect Clin Res. 2020 Jan-Mar;11(1):37- 43. doi: 10.4103/picr.PICR_208_19. Epub 2020 Jan 31. PMID: 32154148; PMCID: PMC7034142. IV. Annapurna SA, Rao SY. New drug and clinical trial rules, 2019: an overview. Int J Clin Trials 2020;7(4):278-84. V. Urooj M, Husain GM, Khan MA, Kazmi MH. Compensation to clinical trial participants in India: A gap analysis. Int J Pharm Investig. 2017 Apr-Jun;7(2):41-46. doi: 10.4103/jphi.JPHI_31_17. PMID: 28929045; PMCID: PMC5553263. VI. Postgraduate Pharmacology by Sougata Sarkar, Paras Medical Publisher, 2020. VII. Orphan Drug Report 2022, by By Melanie Senior and Andreas Hadjivasiliou, April 2022 NDCT 2019 by Akash Agnihotri 49
  • 50. MCQs on NDCT 2019 NDCT 2019 by Akash Agnihotri 50
  • 51. MCQ No. 01 The renewal of the ethics committee must be completed ____________ NDCT 2019 by Akash Agnihotri 51 a) 60 days before the expiry of the license b) 90 days prior to the expiry of the license c) 30 days before the expiry of the license d) 120 days prior to the expiry of the license
  • 52. MCQ No. 02 The validity period of Ethics Committee registration is ____________ NDCT 2019 by Akash Agnihotri 52 a) 1 Year b) 3 Years c) 5 Years d) 10 Years
  • 53. MCQ No. 03 In cases where patients have an expected mortality of 90% or more within 30 days, the quantum of compensation should be: NDCT 2019 by Akash Agnihotri 53 a) ₹ 1 Lakh b) ₹ 2 Lakh c) ₹ 5 Lakh d) ₹ 10 Lakh
  • 54. MCQ No. 04 Before initiating a study involving primary data collection, the Principal Investigator must ensure that various approvals are obtained. Which of the following approvals is absolutely mandatory? NDCT 2019 by Akash Agnihotri 54 a) Scientific committee approval b) Ethics committee approval c) Technical committee approval d) Regulatory authority approval
  • 55. MCQ No. 05 According to the timeline for reporting Serious Adverse Events (SAEs) and the order of compensation from DCGI to the Sponsor, the compensation order should be issued: NDCT 2019 by Akash Agnihotri 55 a) Within 30 days of receipt of the SAE report b) Within 60 days of receipt of the SAE report c) Within 90 days of receipt of the SAE report d) Within 120 days of receipt of the SAE report
  • 56. MCQ’s Answer Key NDCT 2019 by Akash Agnihotri 56 1. b) 90 days prior to the expiry of the license 2. c) 5 Years 3. b) 2 Lakh 4. b) Ethics Committee Approval 5. c) Within 90 days of receipt of the SAE report
  • 57. Thank you NDCT 2019 by Akash Agnihotri 57